Collectively, these data suggest that suppression of Nrf2 enhances CRC cell sensitivity to RSL3 or Erastin-induced ferroptosis but treatment with Nrf2 activator has an opposite effect. The gene discussed is NFE2L2; the disease is colorectal carcinoma.